From Science to Signals, Part II: What the SEC-FDA Cooperation Agreement Means for Life Sciences Companies

The SEC and FDA have formalized an emerging enforcement trend.  We recently described the SEC’s evolving approach to insider trading, predictive markets, and informational advantage in the life sciences sector and observed that enforcement risk was materializing earlier in the information lifecycle. Regulators increasingly focus not simply on whether someone possessed definitive material nonpublic information, but on how evolving scientific insights, regulatory interactions, and probabilistic assessments are generated, interpreted, and used. 

A newly announced Memorandum of Understanding between the SEC and FDA reinforces that trend. The agreement establishes a framework for cooperation and information sharing between the agencies and reflects a shared focus on market integrity, transparency, and FDA-related disclosures by public companies. SEC Chairman Paul Atkins specifically noted that FDA-related disclosures can have a significant impact on financial markets. 

The announcement signifies the broader evolution in how regulators approach the life sciences sector.

For decades, life sciences regulation and securities regulation largely occupied separate spheres: FDA lawyers focused on clinical development, safety, efficacy, manufacturing, and regulatory approvals, while SEC lawyers focused on disclosure obligations, insider trading, and investor communications. In practice, however, there has been overlap. Clinical trial results, regulatory feedback, inspection findings, manufacturing developments, Complete Response Letters, approval decisions, and timing changes may have market effects. Indeed, some of the most significant SEC enforcement cases in the sector have arisen from information generated through the FDA process itself. 

What has changed is how regulators appear to think about that information. As we noted in our earlier discussion of informational advantage, information often develops gradually rather than appearing suddenly. Patient-level data, trends in enrollment, evolving efficacy signals, interactions with regulators, manufacturing discussions, or shifts in anticipated timelines may – if not blinded, and fully appreciable – alter the probability of an outcome long before any formal decision is announced. The SEC increasingly appears willing to examine earlier-stage signals when assessing potential enforcement. 

The new SEC-FDA cooperation framework may accelerate that trend. While the agencies have long had overlapping interests, the formalization of information-sharing procedures creates additional potential for coordination in matters involving FDA interactions, public disclosures, trading activity, and market-moving scientific developments. 

For life sciences companies, the practical implications extend beyond traditional insider trading compliance. Companies may wish to further evaluate:

• How regulatory information is escalated from scientific and regulatory teams to disclosure committees.
• Whether insider trading policies adequately address probabilistic or evolving information.
• Controls surrounding consultants, CROs, expert networks, clinical investigators, and other third parties with potential access to market-sensitive information.
• Alignment between internal discussions of regulatory developments and external communications to investors.
• Governance structures designed to identify and manage informational advantages before they become disclosure or enforcement issues. 

More broadly, the announcement reinforces a theme that is becoming increasingly important across the sector: information governance may be emerging as one of the central regulatory challenges facing life sciences companies. As scientific information becomes more sophisticated, data flows become more complex, and regulators place greater emphasis on market integrity, companies will increasingly need frameworks that connect FDA-facing functions, securities law obligations, disclosure controls, and compliance programs. 

The SEC-FDA MOU does not create new legal obligations. But it signals where agencies intend to focus. For life sciences companies navigating clinical, regulatory, and market-facing risks simultaneously, that signal deserves attention. 

To receive the latest insights on US legal developments, subscribe to the Freshfields A Fresh Take Blog.